Current Heart Failure Reports最新文献_第5页

Fabry Disease: Cardiac Implications and Molecular Mechanisms. 法布里病：心脏影响和分子机制。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-04-01 Epub Date: 2024-01-30 DOI: 10.1007/s11897-024-00645-1

David Weissman, Jan Dudek, Vasco Sequeira, Christoph Maack

{"title":"Fabry Disease: Cardiac Implications and Molecular Mechanisms.","authors":"David Weissman, Jan Dudek, Vasco Sequeira, Christoph Maack","doi":"10.1007/s11897-024-00645-1","DOIUrl":"10.1007/s11897-024-00645-1","url":null,"abstract":"Purpose of review: This review explores the interplay among metabolic dysfunction, oxidative stress, inflammation, and fibrosis in Fabry disease, focusing on their potential implications for cardiac involvement. We aim to discuss the biochemical processes that operate in parallel to sphingolipid accumulation and contribute to disease pathogenesis, emphasizing the importance of a comprehensive understanding of these processes.Recent findings: Beyond sphingolipid accumulation, emerging studies have revealed that mitochondrial dysfunction, oxidative stress, and chronic inflammation could be significant contributors to Fabry disease and cardiac involvement. These factors promote cardiac remodeling and fibrosis and may predispose Fabry patients to conduction disturbances, ventricular arrhythmias, and heart failure. While current treatments, such as enzyme replacement therapy and pharmacological chaperones, address disease progression and symptoms, their effectiveness is limited. Our review uncovers the potential relationships among metabolic disturbances, oxidative stress, inflammation, and fibrosis in Fabry disease-related cardiac complications. Current findings suggest that beyond sphingolipid accumulation, other mechanisms may significantly contribute to disease pathogenesis. This prompts the exploration of innovative therapeutic strategies and underscores the importance of a holistic approach to understanding and managing Fabry disease.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"81-100"},"PeriodicalIF":3.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions-Part II: Combination Therapy. 心力衰竭患者的利尿治疗：当前证据与未来方向--第二部分：联合疗法。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-04-01 Epub Date: 2024-02-01 DOI: 10.1007/s11897-024-00644-2

Cuthbert J J, Cleland J G F, Clark A L

{"title":"Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions-Part II: Combination Therapy.","authors":"Cuthbert J J, Cleland J G F, Clark A L","doi":"10.1007/s11897-024-00644-2","DOIUrl":"10.1007/s11897-024-00644-2","url":null,"abstract":"Purpose of review: Fluid retention or congestion is a major cause of symptoms, poor quality of life, and adverse outcome in patients with heart failure (HF). Despite advances in disease-modifying therapy, the mainstay of treatment for congestion-loop diuretics-has remained largely unchanged for 50 years. In these two articles (part I: loop diuretics and part II: combination therapy), we will review the history of diuretic treatment and current trial evidence for different diuretic strategies and explore potential future directions of research.Recent findings: We will assess recent trials, including DOSE, TRANSFORM, ADVOR, CLOROTIC, OSPREY-AHF, and PUSH-AHF, and assess how these may influence current practice and future research. There are few data on which to base diuretic therapy in clinical practice. The most robust evidence is for high-dose loop diuretic treatment over low-dose treatment for patients admitted to hospital with HF, yet this is not reflected in guidelines. There is an urgent need for more and better research on different diuretic strategies in patients with HF.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"115-130"},"PeriodicalIF":3.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolutions in Combined Heart-Kidney Transplant. 心肾联合移植的演变。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-04-01 Epub Date: 2024-01-17 DOI: 10.1007/s11897-024-00646-0

Rashmi Jain, Michelle M Kittleson

引用次数: 0

Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions - Part I: Loop Diuretics. 心力衰竭患者的利尿治疗：当前证据与未来方向--第一部分：环利尿剂。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-04-01 Epub Date: 2024-01-19 DOI: 10.1007/s11897-024-00643-3

Joseph James Cuthbert, Andrew L Clark

{"title":"Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions - Part I: Loop Diuretics.","authors":"Joseph James Cuthbert, Andrew L Clark","doi":"10.1007/s11897-024-00643-3","DOIUrl":"10.1007/s11897-024-00643-3","url":null,"abstract":"Purpose of review: Fluid retention or congestion is a major cause of symptoms, poor quality of life, and adverse outcome in patients with heart failure (HF). Despite advances in disease-modifying therapy, the mainstay of treatment for congestion-loop diuretics-has remained largely unchanged for 50 years. In these two articles (part I: loop diuretics and part II: combination therapy), we will review the history of diuretic treatment and the current trial evidence for different diuretic strategies and explore potential future directions of research.Recent findings: We will assess recent trials including DOSE, TRANSFORM, ADVOR, CLOROTIC, OSPREY-AHF, and PUSH-AHF amongst others, and assess how these may influence current practice and future research. There are few data on which to base diuretic therapy in clinical practice. The most robust evidence is for high dose loop diuretic treatment over low-dose treatment for patients admitted to hospital with HF, yet this is not reflected in guidelines. There is an urgent need for more and better research on different diuretic strategies in patients with HF.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"101-114"},"PeriodicalIF":3.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139491165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of the Wearable Defibrillator in Heart Failure. 可穿戴除颤器在心力衰竭中的作用。

Current Heart Failure Reports Pub Date : 2024-02-01 Epub Date: 2024-01-18 DOI: 10.1007/s11897-023-00641-x

Thibault Lenormand, Alexandre Bodin, Laurent Fauchier

{"title":"The Role of the Wearable Defibrillator in Heart Failure.","authors":"Thibault Lenormand, Alexandre Bodin, Laurent Fauchier","doi":"10.1007/s11897-023-00641-x","DOIUrl":"10.1007/s11897-023-00641-x","url":null,"abstract":"Purpose of review: Wearable cardioverter defibrillators (WCDs) have been developed as a temporary measure for protecting patients at risk for sudden cardiac death that do not meet the indication for implantable cardioverter defibrillator (ICD), most notably in the early stages of heart failure with reduced ejection fraction before reassessment of their left ventricular ejection fraction. In this review, we report available evidence in the literature and guidelines regarding WCD use in order to try to define the role WCDs may have in heart failure.Recent findings: In the last decade, most observational studies found WCDs to be both safe and effective in terminating ventricular arrhythmias in various indications, mostly centered around heart failure with reduced ejection fraction. The only available randomized controlled trial using WCD did not however show a benefit on patients' survival. Hence, recent guidelines only recommended its use in limited indications. Recent data also suggest a possible interest of WCD in monitoring patients, a finding that may prove useful in the context of new-onset heart failure. Data regarding WCD benefit is scarce, and definitive conclusions on its utility are hard to draw. In the context of heart failure, and particularly new-onset heart failure, WCD might find a role in a global comprehensive management of the disease, both acting as an educational tool, a monitoring tool, and, most importantly, a safe and effective tool in preventing sudden cardiac death. The low level of evidence however invites caution, and the decision of prescribing a WCD needs to be individualized and thoroughly discussed with the patient whose compliance is key with this device.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"33-42"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139484348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex Differences in Circulating Biomarkers of Heart Failure. 心力衰竭循环生物标志物的性别差异。

Current Heart Failure Reports Pub Date : 2024-02-01 Epub Date: 2023-12-07 DOI: 10.1007/s11897-023-00634-w

Roopa A Rao, Anju Bhardwaj, Mrudula Munagala, Sonu Abraham, Sanjana Adig, Arden Shen, Eman Hamad

{"title":"Sex Differences in Circulating Biomarkers of Heart Failure.","authors":"Roopa A Rao, Anju Bhardwaj, Mrudula Munagala, Sonu Abraham, Sanjana Adig, Arden Shen, Eman Hamad","doi":"10.1007/s11897-023-00634-w","DOIUrl":"10.1007/s11897-023-00634-w","url":null,"abstract":"Purpose of revsiew: Evidence is scaling up for sex differences in heart failure; however, clinical relevance of sex-specific differential thresholds for biomarkers is not clearly known. Current ambiguity warrants a further look into the sex-specific studies on cardiac biomarkers and may facilitate understanding of phenotypic presentations, clinical manifestations, and pathophysiologic pathway differences in men and women.Recent findings: Recent studies have confirmed the fact that females have differential threshold for biomarkers, with lower troponin and higher NT proBNP levels. Ambiguity continues to exist in the clinical relevance of ST-2, Galectin 3, and other biomarkers. Novel biomarkers, proteomic biomarkers, and circulating micro RNAs with machine learning are actively being explored. Biomarkers in HFpEF patients with higher female representation are evolving. In recent clinical trials, sex-related difference in biomarkers is not seen despite therapeutic intervention being more effective in females compared to males. Sex-related difference exists in the expression of biomarkers in health and in various disease states of heart failure. However, this differentiation has not effectively translated into the clinical practice in terms of diagnostic studies or prognostication. Active exploration to bridge the knowledge gap and novel technologies can shed more light in this area.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"11-21"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138498033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Trial Designs in Heart Failure: Using Digital Health Tools to Increase Pragmatism. 心力衰竭的新型试验设计：使用数字健康工具提高实用性。

Current Heart Failure Reports Pub Date : 2024-02-01 Epub Date: 2023-12-28 DOI: 10.1007/s11897-023-00640-y

Adam D DeVore, Marat Fudim, Lars H Lund

{"title":"Novel Trial Designs in Heart Failure: Using Digital Health Tools to Increase Pragmatism.","authors":"Adam D DeVore, Marat Fudim, Lars H Lund","doi":"10.1007/s11897-023-00640-y","DOIUrl":"10.1007/s11897-023-00640-y","url":null,"abstract":"Purpose of review: Heart failure is an important clinical and public health issue. There is an urgent need to improve the efficiency of clinical trials in heart failure to rapidly identify new therapies and evidence-based implementation strategies for currently existing therapies. Electronic health (eHealth) platforms and digital health tools are being integrated into heart failure care. In this manuscript, we review opportunities to use these tools to potentially improve the design of and reduce the complexity of clinical trials in heart failure.Recent findings: The PRECIS-2 tool outlines clinical trial design domains that are targets for pragmatism. We believe incorporating pragmatic design elements with the aid of eHealth platforms and digital health tools into clinical trials may help address the current complexity of clinical trials in heart failure and improve efficiency. In the manuscript, we provide examples from recent clinical trials across clinical trial design domains. We believe the current adoption of eHealth platforms and digital health tools is an opportunity improve the design of heart failure clinical trials. We specifically believe these tools can enhance pragmatism in clinical trials and reduce delays in generating high-quality evidence for new heart failure therapeutics.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"5-10"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine? 修正:在心肌肌凝蛋白抑制或心肌肌凝蛋白激活治疗中区分心肌肌钙蛋白水平:药物效应还是煤矿中的金丝雀?

Current Heart Failure Reports Pub Date : 2024-02-01 DOI: 10.1007/s11897-023-00639-5

Matthew M Y Lee, Ahmad Masri

引用次数: 0

Appetite and its Regulation: Are there Palatable Interventions for Heart Failure? 食欲及其调节：心力衰竭有可口的干预措施吗？

IF 3.8

Current Heart Failure Reports Pub Date : 2024-02-01 Epub Date: 2023-12-22 DOI: 10.1007/s11897-023-00637-7

Matthew M Y Lee, Michael E J Lean, Naveed Sattar, Mark C Petrie

{"title":"Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?","authors":"Matthew M Y Lee, Michael E J Lean, Naveed Sattar, Mark C Petrie","doi":"10.1007/s11897-023-00637-7","DOIUrl":"10.1007/s11897-023-00637-7","url":null,"abstract":"Purpose of review: Obesity is a major driver of heart failure (HF) incidence, and aggravates its pathophysiology. We summarized key reported and ongoing randomized clinical trials of appetite regulation and/or dietary energy restriction in individuals with HF.Recent findings: Weight loss can be achieved by structured supervised diet programs with behavioural change, medications, or surgery. The new glucagon-like peptide-1 receptor agonists alone or in combination with other agents (e.g., glucose-dependent insulinotropic polypeptide and glucagon receptor agonists or amylin analogues) potently and sustainably reduce appetite, and, taken together with dietary advice, can produce substantial, life-changing, weight loss approaching that achieved by surgery. To date, data from the STEP-HFpEF trial show meaningful improvements in health status (Kansas City Cardiomyopathy Questionnaire). Effective weight management could relieve several drivers of HF, to complement the existing treatments for HF with both reduced and preserved ejection fraction. Further trials of weight loss interventions will provide more definitive evidence to understand their effects on clinical events in patients with HF.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"1-4"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10827951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rethinking the Impact and Management of Diabetes in Heart Failure Patients. 糖尿病对心力衰竭患者的影响及治疗的再思考。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-02-01 Epub Date: 2023-12-04 DOI: 10.1007/s11897-023-00633-x

Katharina Schütt

引用次数: 0